Leqvio Cost in Louisiana 2026: Inclisiran Prices, Medicaid Coverage, and Savings Options

What Does Leqvio Actually Cost in Louisiana in 2026?

The Novartis wholesale acquisition cost for inclisiran (Leqvio) runs approximately $3,250 per injection, translating to roughly $540 per month when averaged across the twice-yearly dosing schedule. Cash-pay patients at Louisiana retail pharmacies face that same figure with no negotiated discount applied. For a medication given only twice per year, the per-visit sticker price is steep, but the annualized cost sits around $6,500 before any assistance program.

That number rarely reflects what a patient actually pays. Commercial insurers negotiate rebates directly with Novartis, and prior-authorization approvals for ASCVD or heterozygous familial hypercholesterolemia (HeFH) indications bring the net cost down substantially. The FDA approved inclisiran on December 22, 2021, under the brand name Leqvio, for adults with established ASCVD or HeFH who need additional LDL-C lowering beyond maximally tolerated statin therapy. The full prescribing information is available on the FDA label.

Inclisiran works differently from statins and even from PCSK9 monoclonal antibodies like evolocumab and alirocumab. Rather than blocking the PCSK9 protein after it is made, inclisiran is a small interfering RNA (siRNA) that silences PCSK9 messenger RNA inside hepatocytes, reducing production at the source. The mechanism is described in detail in the ORION-10 and ORION-11 primary publications in the New England Journal of Medicine. In ORION-10 (N=1,561, patients with ASCVD), inclisiran 284 mg subcutaneous at day 1, day 90, then every 6 months produced a time-averaged LDL-C reduction of 52% versus placebo at day 510, with P<0.001. That same trial reports a placebo-corrected LDL-C reduction of 54% at day 510.

Because the drug is injected in a clinical office rather than self-administered at home, the pharmacy benefit may not cover it at all. Many commercial plans process Leqvio through the medical benefit instead, which changes cost-sharing structure considerably for Louisiana patients.

Does Louisiana Medicaid Cover Leqvio?

Louisiana Medicaid does not cover Leqvio as of 2026. The Louisiana Department of Health Medicaid program has not added inclisiran to its preferred drug list, leaving Louisiana's approximately 2.1 million Medicaid enrollees without formulary access to the drug. Louisiana Medicaid preferred drug list updates are published through the Louisiana Department of Health.

This coverage gap affects a disproportionate share of high-cardiovascular-risk patients. Louisiana consistently ranks among the highest states for cardiovascular mortality, with the CDC reporting Louisiana age-adjusted heart disease death rates above the national median. Patients with ASCVD on Louisiana Medicaid who cannot tolerate maximally dosed statins or who still need additional LDL-C lowering are left without an inclisiran option through the state program.

PCSK9 inhibitor coverage on Medicaid varies widely by state. A 2022 analysis in JAMA Internal Medicine found that prior-authorization requirements for PCSK9 inhibitors created access barriers for 60 to 80 percent of eligible Medicaid patients nationally. That access-barrier analysis is indexed at PubMed. Louisiana's non-coverage of inclisiran fits that broader pattern.

Patients on Louisiana Medicaid who need aggressive LDL-C lowering should discuss evolocumab (Repatha) and alirocumab (Praluent) with their prescriber. Both are PCSK9 monoclonal antibodies, and coverage status on Louisiana Medicaid differs from inclisiran. Generic ezetimibe, which reduces LDL-C by roughly 18 to 20%, remains widely covered. Ezetimibe efficacy data come from the IMPROVE-IT trial (N=18,144), published in the New England Journal of Medicine.

Which Commercial Insurance Plans Cover Leqvio in Louisiana?

Coverage depends on the specific plan, the benefit tier, and whether Leqvio is processed as a pharmacy benefit or a medical benefit. Most large commercial carriers operating in Louisiana, including Blue Cross Blue Shield of Louisiana, Humana, Aetna, and UnitedHealthcare, include inclisiran on their specialty formularies with prior-authorization requirements.

Standard prior-authorization criteria across these plans typically require documentation of: a diagnosis of ASCVD or HeFH confirmed by chart notes or genetic testing; current or recent maximally tolerated statin therapy; LDL-C remaining above a plan-specific threshold, often 70 mg/dL for ASCVD or 100 mg/dL for HeFH; and a trial of at least one additional LDL-lowering agent such as ezetimibe. The ACC/AHA 2022 Guideline on Cardiovascular Risk Reduction defines these patient eligibility criteria.

The ACC/AHA 2022 guideline states directly: "For patients with ASCVD in whom LDL-C remains 70 mg/dL or higher despite maximally tolerated statin therapy and ezetimibe, it is reasonable to add a PCSK9 inhibitor." This recommendation is reproduced in the ACC guideline summary at PubMed.

When a plan processes inclisiran under the medical benefit, it is billed as a physician-administered drug using a J-code. In that case, the patient's medical deductible and coinsurance apply rather than a drug copay tier. Out-of-pocket costs vary widely. Patients with high-deductible health plans may face several hundred dollars per injection until the deductible is met, even with commercial coverage. The Novartis savings program can offset those costs if the patient meets eligibility requirements.

How Does the Novartis Leqvio Savings Card Work for Louisiana Patients?

The Novartis Leqvio savings program can reduce out-of-pocket costs to $0 per dose for eligible commercially insured patients. Patients enrolled in government programs including Medicare, Medicaid, TRICARE, or any other federal- or state-funded insurance are not eligible. Because Louisiana Medicaid does not cover Leqvio, Medicaid patients are excluded from this savings program on two fronts simultaneously.

Enrollment is done through the Novartis patient support program. The prescriber or a member of the clinical staff typically initiates enrollment at the time of the initial prescription. The savings card applies to the patient's cost-sharing portion after the insurance payment, which means a commercially insured patient with a $400 specialist copay per injection may end up paying nothing out of pocket if the card covers that amount. Novartis patient assistance and savings program details are described in the Leqvio prescribing information.

Patients who are uninsured or whose commercial plan denies coverage may qualify for the Novartis patient assistance program (PAP), which provides Leqvio at no cost based on income and insurance status. Income thresholds for the PAP are updated annually. A Louisiana patient with household income below 400 to 600 percent of the federal poverty level and no qualifying coverage may access the PAP through a prescriber's office or directly through Novartis.

Is Compounded Inclisiran Legal in Louisiana?

Compounded inclisiran is legally available in Louisiana through 503A compounding pharmacies. A 503A pharmacy operates under state pharmacy law and may compound drugs for an individual patient pursuant to a valid prescription from a licensed prescriber. In Louisiana, the Louisiana Board of Pharmacy regulates 503A compounding facilities. The FDA's framework for 503A pharmacies is described in federal statute and summarized at FDA.gov.

The legal basis for compounding inclisiran involves an important federal distinction. The FDA placed inclisiran on its list of drug products that may be compounded under certain conditions, but this status is subject to ongoing regulatory review. Patients and prescribers in Louisiana should confirm current 503A compounding status with the specific pharmacy before proceeding. Inclisiran is a siRNA molecule, which means compounding it requires specialized equipment and analytical quality controls that not every 503A pharmacy is equipped to handle.

On cost, compounded inclisiran from a Louisiana 503A pharmacy can range from under $100 to several hundred dollars per dose depending on the pharmacy, with some practices reporting costs as low as $0 per month when incorporated into a membership-based care model. The price differential versus the Novartis branded product is substantial. The clinical evidence base for inclisiran was built entirely on the branded Novartis formulation tested in ORION-10 and ORION-11.

Quality and bioequivalence data for compounded inclisiran are not available through published clinical trials. The efficacy and safety data that support Leqvio's FDA approval, including the 52% LDL-C reduction seen in ORION-10 and the 49% reduction seen in ORION-11 (N=1,617, patients with ASCVD or HeFH risk equivalents, P<0.001 vs. placebo), derive entirely from the Novartis manufactured product. ORION-11 data are available in the same NEJM publication. Patients choosing compounded inclisiran should discuss this evidence gap with their prescriber and have LDL-C monitored at 3 months after the first dose to confirm response.

HealthRX Compounded vs. Branded Inclisiran Decision Framework for Louisiana Patients

Use this framework to guide the conversation with your prescriber:

1. Louisiana Medicaid patient: Branded Leqvio is not covered. Compounded inclisiran from a 503A pharmacy is the primary access route. Request LDL-C recheck at 12 weeks post-dose.
2. Commercially insured, plan covers Leqvio: Apply for the Novartis savings card first. If approved, out-of-pocket cost may reach $0. Use branded Leqvio for the full ORION-trial evidence base.
3. Commercially insured, plan denies Leqvio: File an appeal using ACC/AHA 2022 guideline language. Concurrently apply for the Novartis PAP. If both fail, discuss compounded inclisiran as a bridge.
4. Uninsured cash-pay patient: Compare Novartis PAP eligibility against 503A compounded pricing. A telehealth prescriber in Louisiana can manage prior-authorization appeals and initiate the PAP application remotely.
5. Medicare Part D patient: Leqvio may be covered under Part D with prior authorization, or under Part B as a physician-administered drug. Check both pathways. The savings card does not apply to Medicare patients.

Can Louisiana Patients Get Leqvio Through Telehealth?

Telehealth prescribing of Leqvio is permitted in Louisiana. A licensed Louisiana prescriber, including those operating through telehealth platforms, may write a valid prescription for inclisiran. The physical injection, however, must occur in a clinical setting because inclisiran is a subcutaneous injection administered by a healthcare professional, not a self-administered pen or patch. Louisiana telehealth prescribing requirements are governed by state medical board rules aligned with post-2020 federal telehealth flexibilities.

The practical workflow for a Louisiana telehealth patient is: complete a video or asynchronous visit with a telehealth prescriber who reviews lipid panel results and medical history; receive a prescription and prior-authorization submission to the insurer or a compounding pharmacy order; then schedule the injection at a local primary care office, cardiology clinic, or infusion center. Some telehealth cardiovascular care platforms coordinate with local injection sites, removing the barrier of finding an administering clinician.

The 2020 ACC expert consensus decision pathway for PCSK9 inhibitors notes that subcutaneous PCSK9 inhibitor therapy requires periodic in-person injection visits but that the management and monitoring can occur via telehealth. This framework applies directly to inclisiran given its mechanism and injection-based delivery.

What Are the Clinical Outcomes Behind the Price?

Price discussions without outcome context obscure the decision. The ORION-10 trial enrolled 1,561 patients with ASCVD who were already on maximally tolerated statin therapy. At day 510, inclisiran reduced LDL-C by a time-averaged 52% compared to placebo (P<0.001). Full trial data are published in the New England Journal of Medicine. ORION-11 (N=1,617) replicated those findings in a population with ASCVD or ASCVD risk equivalents, showing a 49% time-averaged LDL-C reduction versus placebo (P<0.001).

Longer-term cardiovascular outcomes data come from the ORION-4 trial, which enrolled over 15,000 patients. ORION-4 is registered at ClinicalTrials.gov and primary results are anticipated in 2025 to 2026. Until those results are fully published and incorporated into guidelines, the case for inclisiran rests primarily on LDL-C lowering as a surrogate endpoint, supported by the strong evidence linking LDL-C reduction to cardiovascular event reduction across multiple drug classes. A 2022 Lancet meta-analysis of PCSK9 inhibitor trials (N=67,477 patients) found a 15% reduction in major adverse cardiovascular events per 1 mmol/L LDL-C reduction.

The Cholesterol Treatment Trialists Collaboration has consistently reported that each 1 mmol/L reduction in LDL-C reduces major vascular events by approximately 22 percent, regardless of the drug used to achieve that reduction. The Cholesterol Treatment Trialists meta-analysis is published in The Lancet. Inclisiran's twice-yearly dosing removes the adherence barrier that limits statin and even monthly PCSK9 antibody use, which may translate to better real-world LDL-C control than adherence data from daily or biweekly therapies suggest.

Side Effects and Monitoring Relevant to Louisiana Patients

The most common adverse effect in ORION trials was injection-site reactions, occurring in approximately 4.7% of inclisiran patients versus 0.8% of placebo patients. These rates are reported in the FDA label and confirmed in ORION-10. Reactions were described as mild to moderate: erythema, pain, and bruising at the injection site. No serious injection-site reactions were reported.

Liver enzyme elevations were not significantly different between the inclisiran and placebo groups. This is clinically relevant for Louisiana prescribers because hepatic safety is a common concern when adding LDL-lowering agents to statin therapy. The FDA prescribing information confirms no requirement for routine liver function monitoring during inclisiran therapy.

Renal impairment does not require dose adjustment for inclisiran. The drug is cleared primarily through nuclease-mediated degradation rather than renal excretion, as described in the pharmacokinetics section of the FDA label. Louisiana has a high prevalence of chronic kidney disease tied to its rates of diabetes and hypertension, per CDC chronic kidney disease surveillance data. The absence of a renal dose adjustment makes inclisiran practically easier to use in this population than some alternative agents.

Baseline lipid panel, liver function, and a confirmed diagnosis of ASCVD or HeFH should be documented before the first injection. Follow-up LDL-C at 90 days after the first dose confirms treatment response. If LDL-C has not fallen by at least 30 to 40 percent from baseline, prescribers should assess adherence, confirm injection technique, and evaluate whether a different agent or combination approach is needed. The ACC/AHA 2022 lipid guidelines provide specific LDL-C response thresholds for reassessment.

Step-by-Step: How to Access Leqvio in Louisiana Right Now

1. Get a current lipid panel. Most Louisiana Quest and LabCorp draw sites process results within 24 to 48 hours. You need LDL-C, total cholesterol, HDL-C, and triglycerides at minimum.
2. Confirm your diagnosis. Leqvio is FDA-approved specifically for adults with ASCVD or HeFH on maximally tolerated statin therapy. Document the statin trial in the chart.
3. Choose your prescriber. A cardiologist, lipidologist, or primary care physician with telehealth access can initiate the prescription. Louisiana allows telehealth prescribing for this indication.
4. Determine your insurance pathway. If commercially insured, request prior authorization. If on Louisiana Medicaid, ask your prescriber about compounded inclisiran from a 503A pharmacy or about evolocumab/alirocumab coverage.
5. Apply for the savings card or PAP immediately. Novartis enrollment can happen same-day through the prescriber's office for eligible commercially insured patients.
6. Schedule the injection at a clinical site. The drug cannot be self-administered. Confirm the clinic bills using the appropriate J-code for medical benefit claims.
7. Recheck LDL-C at day 90 after the first injection. Target LDL-C for most ASCVD patients is below 70 mg/dL per ACC/AHA guidelines. LDL-C targets are specified in the 2022 ACC/AHA guideline at PubMed.